Johnson & Johnson Announces Plans to Disclose Average Price Increases
As America continues to discuss the increase in the cost of prescription drugs, Johnson & Johnson (J&J) has announced that it plans to disclose average price increases of its prescription drugs.
High and rising prices have also infuriated doctors, insurance companies and politicians, and triggered government probes into the industry's practices. The government has no power now to regulate prices, but the industry appears to be starting to move to deflect further scrutiny and avoid price controls.
With annual price tags topping $100,000 for many new drugs for cancer and rare diseases, some patients have been unable to afford their medicines. Huge price hikes on old products with little competition, like Mylan's EpiPen emergency allergy injectors, also have left some patients scrambling.
"We hope that can create a better understanding of the industry and ... ultimately improve patient access to medicines," Joaquin Duato, head of J&J's prescription drug business, said in an interview Tuesday.
Experts say the company's move will help its image more than patients initially, but it could push other drug makers to tame future price increases and be more transparent. The company says it will divulge average list price increases and what middlemen pay for medicines.
Expected to start in February 2017, J&J will issue annual reports listing the average list and net price increases — but not the figures for individual drugs, as the discounts it gives middlemen are competitive ...
Source: Policy and Medicine - Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
More News: Allergy | Allergy & Immunology | Cancer | Cancer & Oncology | Emergency Medicine | Government | Health Management | Health Medicine & Bioethics Commentators | Insurance | Insurers | Marketing | Politics | Rare Diseases